Nexvet Biopharma plc·4

Nov 20, 1:10 PM ET

Nexvet Biopharma plc 4

4 · Nexvet Biopharma plc · Filed Nov 20, 2015

Insider Transaction Report

Form 4
Period: 2015-11-20
Heffernan Mark
Chief Executive Officer
Transactions
  • Exercise/Conversion

    Option to Purchase Shares

    2015-11-209,2049,203 total(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
    Exercise: $0.13Exp: 2020-11-05Ordinary Shares (9,204 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2015-11-20$0.13/sh+9,204$1,151243,587 total(indirect: By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>)
Holdings
  • Ordinary Shares

    12,084
Footnotes (2)
  • [F1]The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
  • [F2]Options to purchase 9,204 shares vested and became exercisable on 11/5/15, and the remaining 9,203 options to purchase shares will vest and become exercisable on 11/5/16.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT